Perforation

Rx Green Technologies Launches New Ready to Use Coco Grow Bags

Retrieved on: 
Wednesday, April 10, 2024
Nutrient, COGS, Drainage, Plant, Breathability, Water, Perforation, Coco, RTU, Tea

DENVER, April 10, 2024 /PRNewswire/ -- RX Green Technologies ("RX Green"), a leading developer and manufacturer of cannabis cultivation nutrients, growing media, and services, today announces the launch of the newest product in its portfolio: Ready to Use (RTU) Coco Grow Bags. Available in both one- and two-gallon sizes, RTU bags deliver Rx Green's premium, buffered coco in bags specifically designed to support healthy cannabis plant growth from clone to harvest, while also reducing time, labor and resources – ultimately lowering COGs and helping to drive operational efficiency.

Key Points: 
  • Available in both one- and two-gallon sizes, Rx Green's grow bags deliver premium buffered coco in an easy-to-use, efficient design so cultivators can simply Rip.
  • DENVER, April 10, 2024 /PRNewswire/ -- RX Green Technologies ("RX Green"), a leading developer and manufacturer of cannabis cultivation nutrients, growing media, and services, today announces the launch of the newest product in its portfolio: Ready to Use (RTU) Coco Grow Bags .
  • Like all of Rx Green's coco coir products, RTU bags come filled with OMRI-listed clean, buffered coco coir sourced only from RHP-certified sources.
  • "Our RTU bags address that challenge  - delivering premium quality coco in an affordable, easy to use solution."

HealthpointCapital Acquires SteriCUBE®, the Leading Multi-Tray, Safer Sterilization Platform

Retrieved on: 
Wednesday, April 10, 2024
FDA, MTS, ProCare, Hospital, The Company, Perforation, Partner (business rank), Patent, Acquisition, Communication, Marketing, SAN, Sterilization

The SteriCUBE® Multiple Tray Sterilization (MTS) System is a patented, environmentally friendly technology for simultaneous sterilization of instrument-holding trays.

Key Points: 
  • The SteriCUBE® Multiple Tray Sterilization (MTS) System is a patented, environmentally friendly technology for simultaneous sterilization of instrument-holding trays.
  • Simultaneous with the closing of the transaction, HealthpointCapital is bringing in a new leadership team into SteriCUBE.
  • Chris added: "Every day, the sterilization and processing departments of hospitals handle some of the healthcare system's most critical tasks.
  • Schulte, Roth & Zabel LLP and Knobbe Martens Olson & Bear LLP provided legal counsel to HealthpointCapital.

2025 Toyota 4Runner Refines Adventure Ready Heritage

Retrieved on: 
Wednesday, April 10, 2024
Land cruiser, ARB, Radar, Nickel–metal hydride battery, Signature, Corrosion, Tundra, Old, Qi, AC, Control, Perforation, Beyond Zero, Blind spot monitor, OME, MID, Android, Torque, 4Runner, Traction, TRD, PDA, HAC, TNGA-F, Lane departure warning system, SAN, Safety, Mirai, RIGID, Carbon, DNA, BSM, Multimedia, TSS, Sequoia, Sale, Adaptive cruise control, BEV, SR5, Smart key, MAX, Roadside assistance, Road

The all-new 2025 Toyota 4Runner stays true to its original concept, as an extremely capable, dynamic, and durable off-roader and will continue to provide owners a window to bigger worlds.

Key Points: 
  • The all-new 2025 Toyota 4Runner stays true to its original concept, as an extremely capable, dynamic, and durable off-roader and will continue to provide owners a window to bigger worlds.
  • The 2025 4Runner will be built in Toyota Motor Corporation's Tahara plant in Japan and will arrive in the U.S. in the fall of 2024.
  • The 2025 4Runner introduces its first-ever Platinum grade which offers customers a high-end, luxury experience with all the capability you expect in a 4Runner.
  • All 2025 4Runner models come standard with Toyota Safety Sense 3.0, Toyota's suite of active safety and convenience systems.

Olympus Announces FDA Clearance of RenaFlex™, Its First Single-use Flexible Ureteroscope

Retrieved on: 
Tuesday, April 2, 2024
System, U.S. FDA, Burns, Urology, Small Business Saturday, Lithotripsy, Endoscopy, Risk, Patient, Perforation, Infection, Health professional, Bleeding, Ureteroscopy, Kidney, Ureter, Urethra, Physician, Medical imaging

CENTER VALLEY, Pa., April 2, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later date.

Key Points: 
  • The RenaFlex single-use flexible ureteroscope system is used to access and visualize the urinary tract to diagnose and treat urinary diseases and disorders, such as kidney stones.
  • The RenaFlex ureteroscope can be used with endotherapeutic accessories to perform diagnostic and therapeutic procedures within the urinary tract.
  • The RenaFlex Single-use Ureteroscope works in combination with the compatible CV-S1 Video System Center for flexible Single-use Endoscopes.
  • Visit the urology product page for more information about the complete line of Olympus urology solutions.

Olympus Partners with American Lung Association on Patient Education for Lung Cancer Screening

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, Biopsy, Lung cancer, Medicine, Immunotherapy, Disease, Infection, Partnership, Patient, Sore throat, Perforation, Cancer, United, Olympus Corporation, Senior, Lymph, Bleeding, EUS, American Lung Association, Physician, Medical imaging

CENTER VALLEY, Pa., March 27, 2024 /PRNewswire/ -- Olympus Corporation of the Americas, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, is now partnering with the American Lung Association to educate lung cancer patients about the care pathway for diagnosing and staging lung nodules.

Key Points: 
  • The lung nodules educational resources , sponsored by Olympus, help patients understand the diagnosis and staging process for lung nodules and why it is important to their treatment journey.
  • "Olympus is very excited to support this great new educational resource for lung cancer patients through our partnership with the American Lung Association," said Jovan Reyerson, Senior Vice President of Medical and Scientific Affairs at Olympus Corporation of the Americas.
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), a procedure pioneered by Olympus, has helped lay the groundwork for targeted cancer treatment such as immunotherapy.
  • Lung cancer remains the leading cause of cancer death in the United States.² Early detection of lung cancer is key as the 5-year relative survival rate for non-small cell lung cancer is about 65% when caught at a localized stage.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

The Makers of HORMEL® Chili Solve the Double-Dip Dilemma with Double Dippable Chips

Retrieved on: 
Tuesday, March 12, 2024
Food, Social media, Perforation, Cheese

AUSTIN, Minn., March 12, 2024 /PRNewswire/ -- The makers of HORMEL® Chili today launched Double Dippable Chips, the first "breakable" chips designed to allow people to double-dip into their favorite chili dips without committing a social faux pas.

Key Points: 
  • AUSTIN, Minn., March 12, 2024 /PRNewswire/ -- The makers of HORMEL® Chili today launched Double Dippable Chips, the first "breakable" chips designed to allow people to double-dip into their favorite chili dips without committing a social faux pas.
  • After rapid prototyping and some serious break-and-dip testing, Double Dippable Chips are now ready to meet some lucky winners.
  • The party-friendly kits include a bag of Double Dippable Chips, a can of HORMEL® Chili and a recipe for a delicious 7-Layer Chili Cheese Dip.
  • HORMEL® Chili Double Dip Kits will ship to winners just in time to enjoy during the upcoming college hoops tournament.

Pixelle Introduces Premium Ballot Paper Portfolio Designed for U.S. Elections

Retrieved on: 
Monday, March 4, 2024
Office Products, Elections, Campaigns, Public Policy, Government, Specialty, White House, Federal Government, Forest Products, State, Local, Retail, Natural Resources, Democracy, Opacity, Multimedia, Perforation

Pixelle Specialty Solutions (“Pixelle”), a leading manufacturer of specialty papers in North America, launched a new product portfolio of premium ballot papers tailored for local, state and federal elections across the United States.

Key Points: 
  • Pixelle Specialty Solutions (“Pixelle”), a leading manufacturer of specialty papers in North America, launched a new product portfolio of premium ballot papers tailored for local, state and federal elections across the United States.
  • As the 2024 national and local elections draw near, Pixelle is positioned to support polling nationwide with a wide range of high-performance ballot papers that are made in the U.S.A.
  • “Pixelle’s ballot papers are designed to meet the demands of high-volume elections, allowing for efficient and accurate vote tabulation.”
    Pixelle’s ballot paper portfolio includes options for hand-marked ballots, machine-readable ballots compatible with major voting systems, and durable mail-in/absentee ballots.
  • With a new portfolio of premium ballot papers, Pixelle is now applying its technical expertise and production capabilities to support the upcoming elections.

Olympus Distribution of EndoClot® Showing Steady Adoption in the U.S.

Retrieved on: 
Friday, March 1, 2024
Static pressure, Traction, Blood, Physician, Tropical ulcer, Dissection, SIS, Polyp, Starch, Hemostasis, Artifact, Internationalized domain name, AMP, Inflammation, Adenoma, Safety, ESD, GI, Water, Classification, Perforated ulcer, CO2, PHS, Patient, Bleeding, Trauma, Perforation, Medical imaging

EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).

Key Points: 
  • EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).
  • Since their launch, EndoClot products have been discussed in close to 20 relevant professional education courses offered via Olympus Continuum, providing physicians with peer-demonstrations of EndoClot technology capabilities during procedures.
  • "Olympus knew that EndoClot technology would be important to improving procedure efficiencies and contributing to improved patient outcomes," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas.
  • A new video highlighting use of the EndoClot PHS and EndoClot SIS has been developed to provide more information: https://www.youtube.com/watch?v=QlCaoiM2Eo0 .